Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its p1′-pyrrolidinone ring

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3387-3397

  Chang, Yu Chung E ^a   Yu, Xiaxia ^a   Zhang, Ying ^a   Tie, Yunfeng ^b   Wang, Yuan Fang ^a   Yashchuk, Sofiya ^c   Ghosh, Arun K ^c   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRL 02031; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; VIRUS MUTANT;

CARBAMATES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PYRROLIDINONES; SULFONAMIDES;

EID: 84859798097     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300072d     Document Type: Article

References (57)

1. Louis, J. M.; Clore, G. M.; Gronenborn, A. M. Autoprocessing of HIV-1 protease is tightly coupled to protein folding Nature Struct. Biol. 1999, 6, 868-875
2. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690
3. Briggs, J. A.; Riches, J. D.; Glass, B.; Bartonova, V.; Zanetti, G.; Krausslich, H. G. Structure and assembly of immature HIV Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 11090-11095
4. Sepkowitz, K. A. AIDS-the first 20 years N. Engl. J. Med. 2001, 344, 1764-1772
5. Pomerantz, R. J.; Horn, D. L. Twenty years of therapy for HIV-1 infection Nature Med. 2003, 9, 867-873
6. Bartlett, J. A.; Fath, M. J.; Demasi, R.; Hermes, A.; Quinn, J.; Mondou, E.; Rousseau, F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults AIDS (Hagerstown, MD, U.S.) 2006, 20, 2051-2064
7. Grabar, S.; Pradier, C.; Le Corfec, E.; Lancar, R.; Allavena, C.; Bentata, M.; Berlureau, P.; Dupont, C.; Fabbro-Peray, P.; Poizot-Martin, I.; Costagliola, D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor AIDS (Hagerstown, MD, U.S.) 2000, 14, 141-149
8. Ji, J. P.; Loeb, L. A. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro Biochemistry 1992, 31, 954-958
9. Bebenek, K.; Abbotts, J.; Wilson, S. H.; Kunkel, T. A. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots J. Biol. Chem. 1993, 268, 10324-10334
10. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro Antimicrob. Agents Chemother. 2003, 47, 3123-3129
11. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M. P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates Antimicrob. Agents Chemother. 2005, 49, 2314-2321
12. Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Walters, D. E.; Krishnan, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere Bioorg. Med. Chem. Lett. 1998, 8, 687-690
13. Ghosh, A. K.; Dawson, Z. L.; Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV Bioorg. Med. Chem. 2007, 15, 7576-7580
14. Ghosh, A. K.; Leshchenko-Yashchuk, S.; Anderson, D. D.; Baldridge, A.; Noetzel, M.; Miller, H. B.; Tie, Y.; Wang, Y. F.; Koh, Y.; Weber, I. T.; Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1′-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies J. Med. Chem. 2009, 52, 3902-3914
15. Koh, Y.; Das, D.; Leschenko, S.; Nakata, H.; Ogata-Aoki, H.; Amano, M.; Nakayama, M.; Ghosh, A. K.; Mitsuya, H. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro Antimicrob. Agents Chemother. 2009, 53, 997-1006
16. Wlodawer, A.; Gustchina, A. Structural and biochemical studies of retroviral proteases Biochim. Biophys. Acta 2000, 1477, 16-34
17. Weber, I. T.; Agniswamy, J. HIV-1 Protease: Structural Perspectives on Drug Resistance Viruses 2009, 1, 1110-1136
18. Louis, J. M.; Ishima, R.; Torchia, D. A.; Weber, I. T. HIV-1 protease: structure, dynamics, and inhibition Adv. Pharmacol. 2007, 55, 261-298
19. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H. F.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Richman, D. D. Update of the drug resistance mutations in HIV-1: December 2010 Top. HIV Med. 2010, 18, 156-163
20. Louis, J. M.; Zhang, Y.; Sayer, J. M.; Wang, Y. F.; Harrison, R. W.; Weber, I. T. The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts Biochemistry 2011, 50, 4786-4795
21. Rhee, S. Y.; Taylor, J.; Fessel, W. J.; Kaufman, D.; Towner, W.; Troia, P.; Ruane, P.; Hellinger, J.; Shirvani, V.; Zolopa, A.; Shafer, R. W. HIV-1 protease mutations and protease inhibitor cross-resistance Antimicrob. Agents Chemother. 2010, 54, 4253-4261
22. Young, T. P.; Parkin, N. T.; Stawiski, E.; Pilot-Matias, T.; Trinh, R.; Kempf, D. J.; Norton, M. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease Antimicrob. Agents Chemother. 2010, 54, 4903-4906
23. Wiesmann, F.; Vachta, J.; Ehret, R.; Walter, H.; Kaiser, R.; Sturmer, M.; Tappe, A.; Daumer, M.; Berg, T.; Naeth, G.; Braun, P.; Knechten, H. The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? AIDS Res. Ther. 2011, 8, 7
24. Mitsuya, Y.; Winters, M. A.; Fessel, W. J.; Rhee, S. Y.; Hurley, L.; Horberg, M.; Schiffer, C. A.; Zolopa, A. R.; Shafer, R. W. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure AIDS Res. Hum. Retroviruses 2006, 22, 1300-1305
25. Shibata, J.; Sugiura, W.; Ode, H.; Iwatani, Y.; Sato, H.; Tsang, H.; Matsuda, M.; Hasegawa, N.; Ren, F.; Tanaka, H. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case Antiviral Res. 2011, 90, 33-41
26. Santos, A. F.; Soares, M. A. The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors Mem. Inst. Oswaldo Cruz 2011, 106, 177-181
27. Kozisek, M.; Bray, J.; Rezacova, P.; Saskova, K.; Brynda, J.; Pokorna, J.; Mammano, F.; Rulisek, L.; Konvalinka, J. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants J. Mol. Biol. 2007, 374, 1005-1016
28. Mahalingam, B.; Louis, J. M.; Reed, C. C.; Adomat, J. M.; Krouse, J.; Wang, Y. F.; Harrison, R. W.; Weber, I. T. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease Eur. J. Biochem. 1999, 263, 238-245
29. Kovalevsky, A. Y.; Tie, Y.; Liu, F.; Boross, P. I.; Wang, Y. F.; Leshchenko, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M J. Med. Chem. 2006, 49, 1379-1387
30. Mahalingam, B.; Wang, Y. F.; Boross, P. I.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site Eur. J. Biochem. 2004, 271, 1516-1524
31. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes Proteins: Struct., Funct., Genet. 2001, 43, 455-464
32. Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains J. Mol. Biol. 2004, 338, 341-352
33. Tie, Y.; Kovalevsky, A. Y.; Boross, P.; Wang, Y. F.; Ghosh, A. K.; Tozser, J.; Harrison, R. W.; Weber, I. T. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir Proteins: Struct., Funct., Bioinf. 2007, 67, 232-242
34. Bihani, S. C.; Das, A.; Prashar, V.; Ferrer, J. L.; Hosur, M. V. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S Biochem. Biophys. Res. Commun. 2009, 389, 295-300
35. Martinez-Picado, J.; Savara, A. V.; Sutton, L.; D'Aquila, R. T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1 J. Virol. 1999, 73, 3744-3752
36. Shafer, R. W.; Schapiro, J. M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART AIDS Rev. 2008, 10, 67-84
37. Yoshimura, K.; Kato, R.; Kavlick, M. F.; Nguyen, A.; Maroun, V.; Maeda, K.; Hussain, K. A.; Ghosh, A. K.; Gulnik, S. V.; Erickson, J. W.; Mitsuya, H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site J. Virol. 2002, 76, 1349-1358
38. Ide, K.; Aoki, M.; Amano, M.; Koh, Y.; Yedidi, R. S.; Das, D.; Leschenko, S.; Chapsal, B.; Ghosh, A. K.; Mitsuya, H. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano- tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants Antimicrob. Agents Chemother. 2011, 55, 1717-1727
39. Hong, L.; Hartsuck, J. A.; Foundling, S.; Ermolieff, J.; Tang, J. Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant Protein Sci. 1998, 7, 300-305
40. Ido, E.; Han, H. P.; Kezdy, F. J.; Tang, J. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S J. Biol. Chem. 1991, 266, 24359-24366
41. Rose, J. R.; Babe, L. M.; Craik, C. S. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity J. Virol. 1995, 69, 2751-2758
42. Bandyopadhyay, P.; Meher, B. R. Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation Chem. Biol. Drug Des. 2006, 67, 155-161
43. Reiling, K. K.; Endres, N. F.; Dauber, D. S.; Craik, C. S.; Stroud, R. M. Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure Biochemistry 2002, 41, 4582-4594
44. Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M. F.; Maroun, V.; Nguyen, A.; Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.; Erickson, J.; Mitsuya, H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1 Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8675-8680
45. Shao, W.; Everitt, L.; Manchester, M.; Loeb, D. D.; Hutchison, C. A., 3rd; Swanstrom, R. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2243-2248
46. Bagossi, P.; Sperka, T.; Feher, A.; Kadas, J.; Zahuczky, G.; Miklossy, G.; Boross, P.; Tozser, J. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites J. Virol. 2005, 79, 4213-4218
47. Munshi, S.; Chen, Z.; Yan, Y.; Li, Y.; Olsen, D. B.; Schock, H. B.; Galvin, B. B.; Dorsey, B.; Kuo, L. C. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease Acta Crystallogr., Sect. D: Biol. Crystallogr. 2000, 56, 381-388
48. Maibaum, J.; Rich, D. H. Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases J. Med. Chem. 1988, 31, 625-629
49. Liu, F.; Kovalevsky, A. Y.; Tie, Y.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir J. Mol. Biol. 2008, 381, 102-115
50. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Carter, C. W., Jr.; Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol. 276, pp 307-326.
51. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
52. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112-122
53. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr., Sect. A: Found. Crystallogr 1991, 47 (Pt 2) 110-119
54. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
55. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., III; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 2007, 35, W375-W383
56. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
57. The PyMOL Molecular Graphics System, version 1.3; Schrödinger, LLC: Portland, OR, 2010.